The researchers focused on ovarian cancer initially because of their previous research. However, they note that the nanoparticles were originally developed to bind to viruses, and depending on the protein being used, could also bind to proteins on the surface of other cancer cells, bacteria, and viruses. "It's a really interesting approach," said Andre Gobin, a nanoparticle researcher at the University of Louisville. "This opens up the possibility for other therapeutics for many other kinds of cells." Before any potential therapy can be applied to real human patients, the nanoparticles will have to pass clinical trials. The Georgia Tech scientists hope to begin two separate clinical trials within the year. The traditional approach is to bring the nanoparticles to the cancer cells. Researchers would inject the nanoparticles into the body where they would float around and attach onto any cancer cells. Surgeons could then remove the individual cells when they remove the main tumor mass. This method requires extensive testing to ensure there are no unexpected or toxic side effects. The faster way to clinical trials, according to McDonald, is to bring the cancer cells to the nanoparticles. By taking the blood and fluids out of the body and running them through a machine the nanoparticles would act like a filter, grabbing ahold of any cancer cells that pass next to them while the healthy fluids pass back into the body. This way the nanoparticles never enter the body, decreasing the chances of any adverse reaction. "We think we've found a good targeting system for ovarian cancer cells," said McDonald. "Now we just have to think about what else we can target." Related Links: Eric Bland's blog: Interior Design |
advertisement
Put Discovery News on Your Site!
|
-
our sites
-
video
mobile
-
shop
-
stay connected
-
corporate
